Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy

Surgery Today

Volumn 42, Issue 5, 2012, Pages 460-469

  Saigusa, Susumu ^a   Toiyama, Yuji ^a   Tanaka, Koji ^a   Okugawa, Yoshinaga ^a   Fujikawa, Hiroyuki ^a   Matsushita, Kohei ^a   Uchida, Keiichi ^a   Inoue, Yasuhiro ^a   Kusunoki, Masato ^a,b  

^a MIE UNIVERSITY   (Japan)

^b Molec Oncol and Med Biotech Div   (Japan)

Author keywords

3 Bromopyruvic acid; Chemoradiotherapy; GLUT1; Glycolysis inhibitor; Rectal cancer

Indexed keywords

FLUOROURACIL; GLUCOSE TRANSPORTER 1; KI 67 ANTIGEN; RNA; UFT;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER CELL; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL PROLIFERATION; CHEMORADIOTHERAPY; COLORECTAL CANCER; FEMALE; GENE; GENE EXPRESSION; GENETIC ANALYSIS; GENETIC ASSOCIATION; GLUT1 GENE; GLYCOLYSIS; HUMAN; HUMAN CELL; IN VITRO STUDY; LONG TERM CARE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; POSTOPERATIVE PERIOD; PREDICTIVE VALUE; PREOPERATIVE RADIOTHERAPY; PROTEIN FUNCTION; RADIATION DOSE; RECTUM CANCER; RECURRENCE FREE SURVIVAL; RETROSPECTIVE STUDY; SHORT COURSE THERAPY; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; FEMALE; FLUOROURACIL; GENE EXPRESSION; GLUCOSE TRANSPORTER TYPE 1; HUMANS; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; PREOPERATIVE CARE; PROGNOSIS; RECTAL NEOPLASMS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; ROC CURVE; TEGAFUR; TUMOR CELLS, CULTURED; TUMOR MARKERS, BIOLOGICAL;

EID: 84863489200     PISSN: 09411291     EISSN: 14362813     Source Type: Journal    
DOI: 10.1007/s00595-011-0027-2     Document Type: Article

References (31)

1. Warburg O. On the origin of cancer cells. Science. 1956; 123(3191):309-14.
2. Gillies RJ, Robey I, Gatenby RA. Causes and consequences of increased glucose metabolism of cancers. J Nucl Med. 2008; 49(suppl 2):24S-42S.
3. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer. 2004;4(11):891-9.
4. Asano T, Katagiri H, Takata K, Lin JL, Ishihara H, Inukai K, et al. The role of N-glycosylation of GLUT1 for glucose transport activity. J Biol Chem. 1991;266(36):24632-6.
5. Furuta E, Okuda H, Kobayashi A, Watabe K. Metabolic genes in cancer: their roles in tumor progression and clinical implications. Biochim Biophys Acta. 2010;1805(2):141-52.
6. Cantuaria G, Fagotti A, Ferrandina G, Magalhaes A, Nadji M, Angioli R, et al. GLUT-1 expression in ovarian carcinoma: association with survival and response to chemotherapy. Cancer. 2001;92(5):1144-50.
7. Wang BY, Kalir T, Sabo E, Sherman DE, Cohen C, Burstein DE. Immunohistochemical staining of GLUT1 in benign, hyperplastic, and malignant endometrial epithelia. Cancer. 2000;88(12): 2774-81.
8. Brown RS, Wahl RL. Overexpression of Glut-1 glucose transporter in human breast cancer. An immunohistochemical study. Cancer. 1993;72(10):2979-85.
9. Haber RS, Rathan A, Weiser KR, Pritsker A, Itzkowitz SH, Bodian C, et al. GLUT1 glucose transporter expression in colorectal carcinoma: a marker for poor prognosis. Cancer. 1998; 83(1):34-40.
10. Younes M, Lechago LV, Lechago J. Overexpression of the human erythrocyte glucose transporter occurs as a late event in human colorectal carcinogenesis and is associated with an increased incidence of lymph node metastases. Clin Cancer Res. 1996;2(7):1151-4.
11. Sakashita M, Aoyama N, Minami R, Maekawa S, Kuroda K, Shirasaka D, et al. Glut1 expression in T1 and T2 stage colorectal carcinomas: its relationship to clinicopathological features. Eur J Cancer. 2001;37(2):204-9.
12. Chung FY, Huang MY, Yeh CS, Chang HJ, Cheng TL, Yen LC, et al. GLUT1 gene is a potential hypoxic marker in colorectal cancer patients. BMC Cancer. 2009;9:241.
13. Pelicano H, Martin DS, Xu RH, Huang P. Glycolysis inhibition for anticancer treatment. Oncogene. 2006;25(34):4633-46.
14. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun. 2004;324(1):269-75.
15. Geschwind JF, Ko YH, Torbenson MS, Magee C, Pedersen PL. Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. Cancer Res. 2002;62(14): 3909-13.
16. Gatenby RA, Gillies RJ. Glycolysis in cancer: a potential target for therapy. Int J Biochem Cell Biol. 2007;39(7-8):1358-66.
17. Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351(17):1731-40.
18. Guillem JG, Chessin DB, Cohen AM, Shia J, Mazumdar M, Enker W, et al. Long-term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg. 2005;241(5):829-36 (discussion 836-8).
19. Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic- Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355(11):1114-23.
20. Inoue Y, Kusunoki M. Resection of rectal cancer: a historical review. Surg Today. 2010;40(6):501-6.
21. Yoshikawa R, Kusunoki M, Yanagi H, Noda M, Furuyama JI, Yamamura T, et al. Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: a novel target mechanism concept for pharmacokinetic modulating chemotherapy. Cancer Res. 2001;61(3):1029-37.
22. Japanese Society for Cancer of the Colon and Rectum. General rules for clinical and pathological studies on cancer of the colon, rectum and anus. Tokyo: Kanehara; 2006.
23. Bijwaard KE, Aguilera NS, Monczak Y, Trudel M, Taubenberger JK, Lichy JH. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: utility in the diagnosis of mantle cell lymphoma. Clin Chem. 2001;47(2):195-201.
24. Yun J, Rago C, Cheong I, Pagliarini R, Angenendt P, Rajagopalan H, et al. Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells. Science. 2009;325(5947):1555-9.
25. Kim JS, Ahn KJ, Kim JA, Kim HM, Lee JD, Lee JM, et al. Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells: ROSmediated cell death by 3-BrPA. J Bioenerg Biomembr. 2008; 40(6):607-18.
26. Brophy S, Sheehan KM, McNamara DA, Deasy J, Bouchier- Hayes DJ, Kay EW. GLUT-1 expression and response to chemoradiotherapy in rectal cancer. Int J Cancer. 2009;125(12): 2778-82.
27. Rodel C, Martus P, Papadoupolos T, Fuzesi L, Klimpfinger M, Fietkau R, et al. Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol. 2005;23(34):8688-96.
28. Dhadda AS, Dickinson P, Zaitoun AM, Gandhi N, Bessell EM. Prognostic importance of Mandard tumour regression grade following pre-operative chemo/radiotherapy for locally advanced rectal cancer. Eur J Cancer. 2011;47(8):1138-45.
29. Xu RH, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005;65(2):613-21.
30. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, et al. Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer. 2001;85(5): 692-6.
31. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006;66(8): 3992-5.